Open AccessTHE USE OF DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH HEMOPHILIA
Author(s) -
Dzmitry Danilau
Publication year - 2020
Publication title -
gepatologiâ i gastroènterologiâ
Language(s) - English
Resource type - Journals
eISSN - 2708-5309
pISSN - 2616-5546
DOI - 10.25298/2616-5546-2020-4-2-184-188
Subject(s) - medicine , chronic hepatitis , antiviral therapy , hepatitis c virus , chronic liver disease , gastroenterology , antiviral treatment , population , liver disease , hepatitis c , virus , immunology , cirrhosis , environmental health
Background. Worldwide, prior to 1990, a large number of patients with hemophilia were infected with the hepatitis C virus due to substitution therapy. The mortality rate from chronic liver disease and HCC in patients with HCV and hemophilia is signifcantly higher than in general population. Objective. To assess the results of direct-acting antiviral therapy in patients with hemophilia and chronic hepatitis C. Material and methods. The rate of sustained virologic response after DAA treatment and the dynamics of clinical and laboratory parameters during antiviral treatment were evaluated. Results. All 14 patients achieved sustained virological response after 12 / 24 weeks of treatment. During antiviral treatment, some patients showed an increase in blood urea nitrogen, a decrease in leukocyte count, and increase of ALT activity. All these phenomena were reversible and resolved spontaneously. Conclusion. The DAA regimens available in Belarus are highly effective for the treatment of chronic hepatitis C in patients with hemophilia. These regimens do not signifcantly affect hematological parameters, are well tolerated, and have acceptable safety profle.